AngioDynamics Extends Licensing Deal With Interface Biologics To Include CVCs

(RTTNews) - AngioDynamics (ANGO), a provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, and Interface Biologics Inc., a privately-held commercial stage developer of transformative biomedical-polymer products, announced AngioDynamics' exclusive Endexo technology licensing agreement for peripherally inserted catheters or PICCs, ports and dialysis catheters, now includes Central Venous Catheters or CVCs.

Endexo technology is a permanent, non-eluting integral polymer that imparts devices with a passive character demonstrated to have such benefits as reduced platelet and reduced thrombus accumulation on medical devices based on in vitro testing. In contrast to thrombus-resistant coatings or impregnated alternatives, which may be superficial and/or transient, Endexo is incorporated directly into the base polymer to create a material that provides long-term utility and durability without impacting the base underlying mechanical properties of the medical device. The Endexo technology also has significant manufacturing advantages over noted thrombus resistant alternatives as it can be incorporated directly into existing manufacturing processes.

AngioDynamics' BioFlo PICCs with Endexo technology received U.S. Food and Drug Administration clearance in September 2012, and it is similarly approved in Europe and Canada. In August, the Company's BioFlo Port with Endexo technology also received FDA clearance.